Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 1 | P a g e REVIEW ARTICLE Managing Antimicrobial Resistance from Medical and Veterinary Health Sys- tems Perspectives to Achieving Universal Health Coverage in the African Re- gion Istifanus Anekoson Joshua1, Joel Bauche2, Salim Abdulla3 1Department of Community Medicine, College of Medicine, Kaduna State University, Kaduna, Kaduna State, Nigeria 2Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Kaduna State, Nigeria 3Ifakara Health Institute, Box 78373, Dar-es-salaam, Tanzania Corresponding author: Dr. Istifanus Anekoson Joshua, Address: Department of Community Medicine, Kaduna State University, PMB 2339 Tafawa Balewa way, Kaduna State, Nigeria; E-mail: dristifanus@yahoo.com mailto:dristifanus@yahoo.com Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 2 | P a g e Abstract Antimicrobial resistance (AMR) is a threat to global health security and may reverse the gains in preventive medicine. This is worsened by the fact that development of resistance out-paces that of new antimicrobials. The factors driving the development of AMR range from health systems to socio-economic and environmental factors. These include poor antimicrobial stewardship, poor access to quality drugs, prescribing antimicrobials without susceptibility laboratory tests, use of antimicrobials in crop, animal production and aquaculture farming. Others are lack of coordinated medical and veterinary health systems strengthening, poor universal health coverage and practice of one health. The burden of the problem is of public health importance especially in Africa where there is high incidence of poverty, high incidence of out-of-pocket health expenditure, lack of basic social amenities and weak health systems with poor collaboration. The impact of AMR includes increased burden on the healthcare system, hospital admission, cost of patient treatment, poor clin- ical outcomes and impact on food security, among others. In view of the interplay of various sys- tems and factors in the development and emergence of AMR, there is need for multi-sectoral and interdisciplinary approach at global, regional, national and local levels for its prevention and mit- igation. Strengthening of health systems from the medical and veterinary perspectives and univer- sal health coverage are critical in the fight against AMR. The relevant stakeholders include politi- cal leaders, community leaders, health professionals, academics, and research institutions, federal and state ministries of health, agriculture, education and Nongovernmental organisations among others. Keywords: Africa, Antimicrobial resistance, Health systems, Universal Health Coverage Conflict of interest: None declared Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 3 | P a g e Introduction The increasing health threat from emerging infectious diseases and Antimicrobial Re- sistance (AMR) require an urgent global re- sponse, especially in Africa for reasons such as weak medical and veterinary health sys- tems (HS) and high poverty level, among oth- ers. These could reduce access to appropriate, quality antimicrobials and subsequent emer- gence of AMR. Antimicrobial resistance has been described as a global crisis by the United Nations (UN) General Assembly, World Health Organisation (WHO), world leaders of G7 and G20, World Bank (WB), African Union (AU) , European Union (EU); and it is one of the greatest threats to public health requiring urgent global response (1,2,3). It is a trans-boundary problem in which the organisms require no international passport (4). AMR threatens all countries in different ways and to varying extents; and de- spite scanty information, the data available showed evidence of increasing trends of AMR in the African region and the rest of the world (5, 6). This paper discussed antimicro- bial resistance, HS and universal health cov- erage (UHC), their interactions and the po- tential of applying the principle of universal health coverage to prevent/ mitigate the prob- lem of AMR (Figure 1). Methods This paper is a narrative review using searches of peer-reviewed articles published between 1999 and 2020 in databases such as Pubmed, Medline, African Journal online (AJOL), Bioline international, Popline and google scholar; and grey literatures such as reports and research briefs. The words used for search were Africa, Antimicrobial re- sistance, health systems and universal health coverage. Results and Discussion Antimicrobials and antimicrobial re- sistance Antimicrobials are drugs used for the treat- ment of infectious agents such as bacteria, vi- ruses, fungi, parasites and have played prom- inent role in human and veterinary medicine, agriculture and environment (7). They are global public good which have improved health care, saved lives and enhanced eco- nomic gains (8, 9). Antimicrobials are cor- nerstone on which the HS is standing on, not only for the basic treatment of infections, but also for medical and surgical procedures (10, 11). However, the emergence of resistant mi- croorganisms has compromised their effec- tiveness (12). AMR is defined as the devel- opment of resistance in a microorganism to an antimicrobial agent to which it was previ- ously sensitive (13). Access to quality antibi- otics which is a subset of antimicrobials used to treat bacteria is very essential in the treat- ment and prevention of resistance. In Africa, AMR has been documented to be a problem for HIV and the pathogens that cause tuber- culosis (TB), typhoid, meningitis, gonorrhea; Bovine TB, Pseudomonas oryzae and Pseu- dononas syringae infections (1,14 ,15). Sixty percent of pathogens harmful to humans are of animal origin; humans and animals share the same bacteria (9). Drivers of antimicrobial resistance Many factors are contributing to the emer- gence and spread` of AMR globally and in Africa. These include the overuse and misuse Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 4 | P a g e Figure 1: Chart showing the links between universal Health Coverage, Health Systems and Antimicrobial Resistance. Universal Health Coverage Decrease Antimicrobial Resistance Medical and Veterinary Health Systems Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 5 | P a g e of antimicrobials, sub-optimal infection con- trol, use of antibiotics as massive depot prep- aration in animal production with no observe of withdrawal periods, antimicrobial agents use for growth promotion in animal hus- bandry, use of substandard and/ or counterfeit drugs in both medical and veterinary prac- tices, poor capacity to conduct antimicrobial susceptibility testing, among others (1, 16, 17, 18, 19). The transmission of AMR is ac- celerated by impaired access to potable wa- ter, limitations in public health prevention programs such as immunization and sanita- tion (1). Vaccination of humans and animals is a very effective way to prevent them from becoming infected, thereby reducing the need for antibiotics for the infections that do not have existing vaccines (20). The develop- ment of AMR and its spread to other organ- isms via mobile genetic elements (plasmids and transposons) has been amplified by in- dustrial discharges (pharmaceutical, agricul- tural) and human wastes contaminating the environment (21). In addition, antimicrobials are used to treat human, animal and plant dis- eases, depending on the species treated and particular drug used, 10- 80% of the drug used is absorbed or metabolized, while the re- mainder are excreted as active compounds through urine and faeces into the environ- ment (21). Manure and waste water are used as fertilizers in farms and sub-therapeutic an- timicrobials used for treatment can serve as selective forces in AMR emergence (21). An- timicrobial resistant genes and bacteria with resistance to one or more drugs have been de- tected in surface waters, in soils, in animal feeds and on edible plants globally (21). Food is likely to be quantitatively the most important potential transmission pathway from livestock to humans, although direct ev- idence linking AMR in humans to food con- sumption is lacking (22). The use of antibiot- ics in chicken could cause resistance in hu- mans; and MRSA in animals have been linked with that in humans (23, 24, 25, 26, 27). The globalizations of trade in food prod- ucts, conventional and medical tourisms fa- cilitate the spread of resistant bacteria (9). So- cioeconomic status has also been shown to have an influence on what antibiotic agents are prescribed and association with resistance and the linkages between poverty and AMR (28, 29, 30). Poor people are less likely to seek for medical prescription when indicated and may not afford complete treatment with adequate dose of antimicrobials (30). The burden of antimicrobial resistance The economic burden of AMR is difficult to calculate due to insufficient data and the need to account for externalities especially in Af- rica (31). However, estimates of the impact of AMR on the US economy are exceedingly high, including $20 billion in direct health care costs with additional indirect costs as high as $25 billion, 2 million illnesses and 23000 deaths per year(32). The WB projects that 24 million people could fall into extreme poverty by 2030 because of AMR and most would come from low and middle income countries. Globally, AMR is estimated to ac- count for more than 700,000 deaths per year and if current trends continue, it will cost ap- proximately 10 million lives per year and over US$100 trillion in lost output globally by 2050 (4). It has been estimated that about 4,150,000 deaths will be attributed to AMR in Africa by 2050 (4, 13, 33).The increase in AMR could lead to a reduction in options available to treat infectious diseases, support Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 6 | P a g e chemotherapy, surgery, and this will have a significant impact on the HS and economies (13). Infections with resistant organisms have been associated with increased hospital stay, increased morbidity and mortality, use of ad- ditional drugs, laboratory tests and increased treatment cost (34, 35). This has financial im- plications for the individuals, families, com- munities and the HS (13). This has increased poverty as it has been documented that mil- lions of Africans fall into poverty due to high out of pocket health payments (36). AMR could lead to loss of productivity from the spread of diseases to other animals and death of the animals, thereby threatening the sus- tainability and security of food production and the livelihood of farmers. Drug related causes of AMR and health systems Poverty has been cited by WHO as a major force driving development of AMR (37). In developing countries factors such as inade- quate access to effective drugs, unregulated dispensing and manufacture of antimicrobi- als related to cost are contributory (37). While in America, poverty-driven practices such as medication-sharing, use of “leftover” antibiotics, the purchase and use of foreign- made drugs of questionable quality are likely contributing to AMR; this has also been re- ported in Africa (38). In many HS, wide- spread inappropriate use of antibiotics com- bined with inadequate access especially for the poor contributes to the problem of AMR (5). Poor collaboration between the human and veterinary/animal health sectors is also a problem. Little data exist about the individual practices of veterinarians in Africa and most antibiotic prescriptions are used during ani- mal production. Veterinary antibiotics can be purchased on the open market just as human antibiotics and the lack of separation of anti- biotics used for animals and that for humans, which have negative public health conse- quences. Lack of stringent penalties on man- ufacturing and distribution of substandard and counterfeit drugs in Africa is also a chal- lenge (39). What has been done in response to AMR? The WHO 2015 Global Action Plan on AMR underscores the need for collaboration be- tween human, animal, food and environmen- tal sectors (7). Also, the WHO 2018 compe- tency framework for health workers’ educa- tion and training on AMR has four main AMR domains, namely building awareness of AMR, appropriate use of antimicrobials, infection prevention and control and diagnos- tic stewardship (40). In Africa, the Africa Centre for Disease Control and Prevention (Africa CDC) has established the AMR Sur- veillance Network (AMRSNET) which is a network of public health institutions and leaders from human and animal health sec- tors who will collaborate to measure, prevent, and mitigate harms from resistant organisms. AMRSNET’s four goals are: improve sur- veillance of AMR organisms among humans and animals; delay emergence of AMR; limit transmission of AMR and mitigate harm among patients infected with AMR organ- isms (1). The Tripartite collaboration be- tween WHO, Food and Agricultural Organi- sation (FAO) and the World Organisation for Animal Health (OIE) has provided critical leadership to foster concerted efforts aimed at combating the threat of AMR at a global level in recent years but remains seriously under- resourced (41, 42). Nigeria, being the most populated country in West Africa has to take Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 7 | P a g e the lead in tackling AMR using the ‘One Health’ approach, which acknowledges the links among humans, animals and the envi- ronment as the corner stone of its plan (39). The government has focused on good leader- ship, multidisciplinary approach, enforce- ment of regulations, public education and community participation on tackling the growing AMR problem (39). The medical and veterinary health systems Health system consists of all organizations, people and actions whose primary intent is to promote, restore or maintain health (43). A good HS should be “STEEEP”, namely safe, timely, effective, efficient, equitable and pa- tient-centred. The WHO Health System framework describes HS in terms of six core components or “building blocks”, which are leadership/governance, health workforce, fi- nancing, service delivery, health information system and access to essential medicine, an- tibiotics inclusive. Therefore, to preserve an- tibiotic effectiveness, interventions need to be implemented throughout the whole HS and the whole of society (11). Universal Health Coverage Universal Health Coverage which is the ac- cess by all who need all basic health care ser- vices at a cost that will not expose them to financial hardship. It has the advantage of eq- uity, quality, efficiency, accountability, sus- tainability and resilience. UHC include finan- cial risk protection, access to essential healthcare services, access to safe, effective, quality and affordable essential medicines and vaccines for all. The role of UHC is vital in order to have access to these essential med- icines in Africa in particular, where majority of people pay for healthcare with out-of- pocket expenditure (35, 36). It ensures access by all people, to all quality services at cost not exposing them into financial difficulties, and it is central to improved access to quality drugs e.g. antimicrobials. Financial access is crucial in view of the high poverty level and burden of infectious diseases in Africa (35). An estimated 11 million people become poor each year and one-third of Africans in need of healthcare do not have access because of financial barrier (36, 44). The UHC ensures that every citizen gets at least the minimum health package by the system. Health system could have structured financing mechanism in which the government pays for the people and the one in which the people contribute. However, a pooling financing mechanism (from government or insurance) could help in risk sharing and resources allocation for ma- jority of the citizens. The National Health In- surance Scheme (NHIS) is the best way to fi- nance the HS whereby both government and individual have responsibilities for health and the mechanism gives people better access to healthcare. However, the NHIS in Nigeria mainly captures the formal sector (about 10% of the population) (45). Many countries in the region have 3 key financing sources namely, donor funding, OOP payment and tax-based government financing. OOP payments have increased in nearly all countries, and the re- gional average has increased from US$15 per capita in 1995 to US$38 in 2014 (36), and OOP spending for health care services in Ni- geria is among the highest in the world with 72% [39]. This could lead to poor access to quality healthcare and quality antimicrobial which will result in AMR. Out-of-pocket payment is the simplest financing mecha- nism, and because it does not ensure equity and financial risk protection, it is universally Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 8 | P a g e agreed to be the worst way to finance HS (46). Here the health services are according to ability to pay not need. The UHC as an ap- proach that is linked to financing mechanism, it has health, political and economic benefits (46), and can provide an ideal platform to manage AMR through adequate provision and rational use of antimicrobials (Table 1). The health system attributes and the UHC ac- tions for addressing AMR include equity, quality, efficiency, accountability, sustaina- bility and resilience. Universal Health Cover- age can build system governance and coordi- nation capacities that are highly relevant to tackling AMR (47). Government can take in- formed decisions and wisely allocate health investment in areas such as training of health workers, strengthening of medical and veter- inary systems, improved health information, effective infection prevention and control program, vaccines and evidence-based anti- biotic stewardship program, research and de- velopment (26, 33, 48). For the any UHC to be successful, the relevant stakeholders such as political leaders, community leaders, health professionals, academics, and research institutions, federal and state ministries of health, agriculture, and education and Non- governmental organisations need to work to- gether. Health Financing In the Abuja declaration of April 2001, the Heads of States of the AU countries pledged to set the target of at least 15% of the annual budgets to improve the health sector. How- ever, only four countries met the Abuja target of 15 percent of general government spend- ing in 2014. Limited commitment of domes- tic resources is often reflected in shortages of critical inputs namely- manpower, materials, money and minute (4Ms). Financial protec- tion is generally low in Africa, requiring most patients to pay for health services from their own household income (OOP payments). Out-of-pocket payment for health services predisposes person or families to catastrophic health expenditure and poverty. In addition, it does not allow pooling of resources and risk sharing that is beneficial to the sick persons and government. Access to essential medicines Sub-standard and counterfeit antibiotics are widely available in Africa and have a sub- stantial negative impact on the medical and veterinary health systems. They facilitate AMR and worsen case-fatality. Patients with infectious diseases that are not properly treated could develop complications requir- ing second-line medications that are very ex- pensive; and sometimes may result in poor health outcomes. This can also happen in the veterinary hospitals/clinics. Nigeria is among the 10 countries projected to have increased antibiotics use in veterinary medicine by 2030 (25). Leadership/governance Accelerating progress toward UHC in Africa is within reach but will require political lead- ership and a clear strategic vision (36). The quality of leadership and stewardship varies at all levels of the health sector, from the top positions in the health down to officers’ in- charge of hospitals or health centres. Laws and policies play critical roles in framing, en- abling, and protecting public health. The AU and Africa CDC have been playing important role. Issues such as regulations for antimicro- bials in food and feed, strengthening of anti- Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 9 | P a g e Table 1: Entry-points for integrating AMR into Universal Health Covering using the Health Systems elements (Adapted from reference 43) Element of Health Systems Measures to tackle antimicrobial resistance Service delivery -Provision of clean water, sanitation, immunization, infection prevention and control -Facilitate rational drug use through diagnostics and primary health care - increase investment in veterinary services and animal health Health workforce -Invest in professional education, training, certification and development as well as regulation of professionals. - Joint scientific meetings and conferences by medical and veterinary profes- sionals and other stakeholders Health information systems -Strengthen monitoring and surveillance across networks focusing on labora- tories and set standards for diagnostics. Access to essential medicines -Ensure antimicrobials are accessible, but not used irrationally. This requires linking access with ensuring responsible use -Use alternatives to antibiotics such as probiotics, prebiotics, organic acids, exogenous enzymes and essential oils among others as growth promoters in animal production Health financing -Consider antimicrobial resistance a risk to both the sustainable financing of universal health coverage and the individual’s ability to pay for higher cost of treatment -Approach financing of universal health coverage through an antimicrobial resistance-lens -Delink health worker income and profit of companies and institutions from the volume of antimicrobials sold. Leadership/governance -Strong political leadership, advocacy and accountability -The impact of antimicrobial resistance goes beyond health care, and systems changes should therefore be applied to the agricultural and environmental sectors - Regulations on antimicrobial use and prevention of infections. Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 10 | P a g e microbial policies, engaging civil society or- ganisations and standard treatment guidelines for human, terrestrial and aquatic animals, plants and environment are very crucial (1,41). Health workforce Health professionals are the most critical in- put in the delivery of health services and functioning of any HS. Sufficient human re- sources with adequate education and skills are needed for AMR surveillance and control in both human and animal health sectors (1). Africa CDC has identified the need to pro- mote stewardship programs to increase the proportions of physicians and veterinarians adhering to prudent antibiotic use guidelines, which will help delay emergence of AMR and improve outcomes among patients al- ready infected with AMR organisms (1). Service delivery Health care services should be people-cen- tred, qualitative, target the poor and margin- alized, including those in hard-to-reach areas (35) which will improve access to basic ser- vices to the majority. However, infrastructure in most government facilities in some Afri- can countries is poor; hospital wards, outpa- tient clinics, health centres and health posts, along with their water and electricity supplies and sanitation are usually in need of repair, renovation or expansion. Enhancing capacity of the health care workers will improve the quality of the health services, better health status of the people and animal and reduced incidence of sickness. Health information systems The critical need for timely, relevant and re- liable medical and veterinary data to support evidence-based decision making is very im- portant. Evidence based information is re- quired to facilitate behavioural changes on appropriate use of antimicrobials and safe- guard human and animal health (41). Health data is very essential for planning, delivery of evidence based health care services, research and tracking of HS (42). Real time and relia- ble data will help in the planning of the med- ical and veterinary services, identification of gaps and optimization of services. Updated antibiogram results will help in rational use of antibiotics and reduced misuse, which will decrease the emergence of AMR in medical and veterinary health sectors. The one health concept One Health is a collaborative effort of multi- ple disciplines working locally, nationally, and globally to obtain optional health for peo- ple, animals and our environment (47). One health is a public good that has the potential to mitigate the negative externality of AMR (47). The Canadian Science center for Hu- man and Animal Health is the first organiza- tion worldwide to house in one facility the la- boratory for human and animal diseases re- search (47). Studies have shown that imple- menting one health especially in low income countries will save lots of money for the vet- erinary and medical health systems (49). This money can be used to enhance surveillance and improve capacities in medical and veter- inary HS. Surveillance systems are the foun- dation for a better understanding of the epi- demiology of AMR and the key for tackling this public health threat (33, 50). Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 11 | P a g e Conclusion Universal Health Coverage is an important approach to combat AMR through medical and veterinary HS strengthening as AMR is a threat to social, economic, health and devel- opment. Also tackling AMR will require rel- evant stakeholders and concerted, multi-sec- toral and multi-disciplinary approach at global, regional, national and local levels that is sustainable. References 1. Africa Centres for Disease Control and Prevention: Framework for Anti- microbial Resistance 2018-2023. Af- rican Union. 2. https://africacdc.org/download/af- rica-cdc-framework-for-antimicro- bial-resistance/ (Accessed 20 July, 2020). 3. UN General Assembly, 2016, Reso- lutions of the 71st session. www.un.org/en/ga/71/resolu- tions.shtml ( Accessed 4 May 2017). 4. European Centre for Disease Preven- tion and Control (ecdc). Country Mission Latvia: Antimicrobial Re- sistance. Stockholm: European Cen- tre for Disease Prevention and Con- trol, 2013. 5. O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations May 2016. www.amr-review.org/sites/de- fault/files/160525_Final%20pa- per_with%20cover.pdf) (Accessed 15 April, 2020). 6. Akinde OS and Taiwo MO. Emerg- ing Antibiotic Resistance in Africa, Threat to Healthcare Delivery. MOJ Biology and Medicine 2017; 1 (4):00023. DOI: 10.15406/mo- jbm.2017.01. 7. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schäberle TF, Hughes DE, Epstein S. A new antibiotic kills pathogens without detectable re- sistance. Nature 2015; 517, 455-459. 8. World Health Organization. World- wide Country Situation Analysis: Response to Antimicrobial Re- sistance. Geneva: WHO, 2015. 9. Piddock LJV. The crisis of no new antibiotics- what is the way forward. The Lancet Infectious Diseases 2012; 12 (3): 249-253. 10. FAO/OIE/WHO fact sheets on Anti- microbial Resistance, 2015. https://rr-africa.oie.int/wp-con- tent/uploads/2019/09/antibio_en.pdf (Accessed 20 July, 2020) 11. Laxminarayan RM et al, ’Antibiotic resistance—the need for global solu- tions,’ The Lancet Infectious Dis- eases 13, (2013): 1057–1098. 12. Mpundu M. Antimicrobial Re- sistance and Sustainable Develop- ment: A Planetary Threat but a Fi- nancing Orphan’, (Report, ReAct – Action on Antibiotic Resistance & Dag Hammarskjöld Foundation, 2018). https://www.react- group.org/wp-content/up- loads/2019/09/Antimicrobial-re- sistance-and-univer sal-health-cover- age-Whats-the-deal-ReAct-Sept- 2019.pdf (Accessed 10 July, 2020) https://africacdc.org/download/africa-cdc-framework-for-antimicrobial-resistance/ https://africacdc.org/download/africa-cdc-framework-for-antimicrobial-resistance/ https://africacdc.org/download/africa-cdc-framework-for-antimicrobial-resistance/ http://www.un.org/en/ga/71/resolutions.shtml http://www.un.org/en/ga/71/resolutions.shtml http://www.amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)%20(Accessed http://www.amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)%20(Accessed http://www.amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)%20(Accessed https://rr-africa.oie.int/wp-content/uploads/2019/09/antibio_en.pdf https://rr-africa.oie.int/wp-content/uploads/2019/09/antibio_en.pdf https://www.reactgroup.org/wp-content/uploads/2019/09/Antimicrobial-resistance-and-univer%20sal-health-coverage-Whats-the-deal-ReAct-Sept-2019.pdf https://www.reactgroup.org/wp-content/uploads/2019/09/Antimicrobial-resistance-and-univer%20sal-health-coverage-Whats-the-deal-ReAct-Sept-2019.pdf https://www.reactgroup.org/wp-content/uploads/2019/09/Antimicrobial-resistance-and-univer%20sal-health-coverage-Whats-the-deal-ReAct-Sept-2019.pdf https://www.reactgroup.org/wp-content/uploads/2019/09/Antimicrobial-resistance-and-univer%20sal-health-coverage-Whats-the-deal-ReAct-Sept-2019.pdf https://www.reactgroup.org/wp-content/uploads/2019/09/Antimicrobial-resistance-and-univer%20sal-health-coverage-Whats-the-deal-ReAct-Sept-2019.pdf https://www.reactgroup.org/wp-content/uploads/2019/09/Antimicrobial-resistance-and-univer%20sal-health-coverage-Whats-the-deal-ReAct-Sept-2019.pdf Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 12 | P a g e 13. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and re- sistance. The New England Journal of Medicine 2013; 368 (4):299-302. 14. World Health Organization (WHO). Antimicrobial Resistance Global Re- port on Surveillance. Geneva: WHO, 2014. 15. González-Lamothe R, Mitchell G, Gattuso M, Diarra MS, Malouin F, Bouarab K. Plant Antimicrobial Agents and Their Effects on Plant and Human Pathogens. International Journal of Molecular Sciences 2009, 10: 3400-3419. 16. Boutayeb A. The Impact of Infec- tious Diseases on the Development of Africa. In: Preedy VR., Watson RR. (eds) Handbook of Disease Bur- dens and Quality of Life Measures. Springer, New York, NY, 2010. 17. European Commission. An European one health action plan against anti- microbial resistance, 2017. www.ec.europa.eu/health/amr (Ac- cessed 2 August, 2020). 18. Knobler SL, Lemon SM, Najafi M, et al., editors. Washington (DC): Na- tional Academies Press (US); 2003. The Resistance Phenomenon in Mi- crobes and Infectious Disease Vec- tors: Implications for Human Health and Strategies for Containment: Workshop Summary. Institute of Medicine (US) Forum on Emerging Infections. 19. Mathew AG, Cissell R, Liamthong S. Antibiotic Resistance in Bacteria Associated with Food Animals: A United States Perspective of Live- stock Production. Foodborne Patho- gens and Disease 2007; 4(2):115– 133. 20. Prestinaci F, Pezzotti P, Pentosti A. Antimicrobial Resistance: A global multifactorial phenomenon. Pathog Glob Health 2015; 109: 309-318. 21. Marquardt RR and Li S. Antimicro- bial resistance in livestock: advances and alternatives to antibiotics. Ani- mal Frontiers 2018; 8 (2): 30–37. 22. Food and Agriculture Organization (FAO), World Organisation for Ani- mal Health, World Health Organiza- tion. Tripartite Monitoring and Eval- uation (M&E) framework for the Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2019. 23. Wall BA, Mateus A, Marshal L, Pfeiffer DU. Lubroth J, Ormel HJ, Otto P, Patriarchi A. Drivers, Dy- namics and Epidemiology of Antimi- crobial Resistance in Animal Produc- tion. Food and Agricultural Organi- sation of the United Nations. www.fao.org/3/a-i6209e.pdf (Ac- cessed 10 July, 2020) 24. Rousham EK, Unicomb L, Islam, M.A. Human, animal and environ- mental contributors to antibiotic re- sistance in low-resource settings: In- tegrating behavioural, epidemiologi- cal and One Health approaches. Proc. R. Soc. B Biol. Sci. 2018, 285, 20180332. http://www.ec.europa.eu/health/amr http://www.fao.org/3/a-i6209e.pdf Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 13 | P a g e 25. Nadimpalli M, Delarocque-Astag- neau E, Love DC, Price LB, Huynh BT, Collard JM, Lay KS, Borand L, Ndir A, Walsh TR et al. Combating global antibiotic resistance: Emerg- ing one health concerns in lower-and middle-income countries. Clin. In- fect. Dis. 2018, 66, 963–969. 26. Van Boeckel TP, Pires J, Silvester R, Zhao C, Song J, Criscuolo NG,Gil- bert M, Bonhoeffer S, Laxminarayan R. Global trends in antimicrobial re- sistance in animals in low-and mid- dle-income countries. Science 2019, 365, eaaw1944. 27. O’Neill,J.;Da- vies,S.;Rex,J.;White,L.J.;Mur- ray,R.ReviewonAntimicrobialRe- sistance,TacklingDrug-Resistant In- fections Globally: Final Report and Recommendations; Wellcome Trust and UK Government: London,UK, 2016. 28. Lazarus B, Paterson DL, Mollinger JL, Rogers BA. Do human ex- traintestinal Escherichia coli infec- tions resistanttoexpanded-spec- trumcephalosporinsoriginatefrom- food-producinganimals? A system- atic review. Clin. Infect. Dis 2014, 60, 439–452. 29. Glass SK, Pearl DL, McEwen SA, Finley R. Canadian province-level risk factor analysis of macrolide con- sumption patterns (2000–2006). Journal of Antimicrobial Chemother- apy 2010a; 65:148–555. 30. Glass SK, Pearl DL, McEwen SA, Finley R. A province-level risk fac- tor analysis of fluoroquinolone con- sumption patterns in Canada. Journal of Antimicrobial Chemotherapy 2010b; 65:2019–2027. 31. Okeke, IN. Antimicrobial Resistance in Developing Countries. Springer; New York: 2010. Poverty and Root Causes of Resistance in Developing Countries; p. 27-35. 32. Howard DH, Scott DR. The Eco- nomic Burden of Drug Resistance. Clinical Infectious Diseases 2005; 41:S283–286. 33. US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013. http://www.cdc.gov/dru- gresistance/threat-report- 2013/pdf/ar-threats-2013-508.pdf (Accessed July 24, 2014). 34. World Bank. Drug resistant infec- tions: A threat to our economic fu- ture, Washington, 2017. 35. Wolkewitz M, Frank U, Philips G, Schumacher M, Davey P. for the BURDEN Study Group. Mortality associated with in-hospital bactere- mia caused by Staphylococcus au- reus: a multistate analysis with fol- low-up beyond hospital discharge. Journal of Antimicrobial Chemother- apy 2011; 66:381–386. 36. Alsan M, Schoemaker L, Eggleston K, Kammili N, Kolli P, Bhattacharya J. Out-of-pocket health expenditures and antimicrobial resistance in low- and middle-income countries. Lancet Infectious Diseases 2015 October; 15(10): 1203–1210. 37. Universal Health Coverage in Africa: Framework for Action, International Bank for Reconstruction and Devel- opment. World Bank, 2016. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 14 | P a g e 38. Margaret B and Planta MD. The Role of Poverty in Antimicrobial Re- sistance. J Am Board Fam Med 2007, 20: 533-539. 39. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral fac- tors leading to acquired bacterial re- sistance to antibiotics in developing countries. Emerg. Infect. Dis. 1999; 5, 18. 40. Antimicrobial Use and Resistance in Nigeria: Situation Analysis and Rec- ommendations. A publication of Federal Ministries of Agriculture, Environment and Health, 2017. https://ncdc.gov.ng/themes/com- mon/docs/proto- cols/56_1510840387.pdf 41. European Commission. Special Eu- robarometer 478 Report Antimicro- bial Resistance, 2018. www.ec.eu- ropa.eu/commfrontoffice/pub- licopinion/index.cfm/Survey/getSur- veyDetail/instruments/SPECIAL/sur- veyKy/2190 (Accessed 2 August, 2019). 42. 2017- 2027 Multi-sectoral National Action Plan on Antimicrobial Re- sistance. Government of the Repub- lic of Zambia. www.afro.who.int/publica- tions/multi-sectoral-national-action- plan-antimicrobial-resistance-2017- 2027(Accessed 10 July, 2020). http://documents1.worldbank.org/cu- rated/en/735071472096342073/pdf/1 08008-v1-REVISED-PUBLIC- Main-report-TICAD-UHC-Frame- work-FINAL.pdf (Accessed 30 May, 2020). 43. No time to wait: Securing the future from drug-resistant infections; Re- port to the Secretary-General of United Nations, April, 2019. ww.who.int/antimicrobial-re- sistance/interagency-coordination- group/IACG_final_sum- mary_EN.pdf?ua=1 United Nations. Political Declaration of the High- level Meeting of the General Assem- bly on Antimicrobial Resistance, A/71/L.2.(Accessed 22 September 2016). 44. World Health Organization. Every- body’s business - Strengthening health systems to improve health outcomes. WHO’s framework for ac- tion. Geneva, WHO, 2007. http://www.who.int/healthsys- tems/strategy/everybodys_busi- ness.pdf (Aaccessed 26 April 2010). 45. The first WHO Africa Health forum: putting people first. The road to uni- versal health coverage in Africa, Ki- gali-Rwanda 27-28 June 2017.www.afro.who.int/publica- tions/first-who-africa-health-forum- report (Accessed 20 May, 2020). 46. Aregbeshola B. Health care in Nige- ria: Challenges and recommenda- tions, 2019. www.socialprotec- tion.org/discover/blog/health-care- nigeria-challenges-and-recommenda- tions(1 September, 2019) 47. WHO 2013. Arguing for Universal Health Coverage. www.apps.who.int/iris/bit- stream/han- dle/10665/204355/9789241506342_e ng.pdf?sequence=1&isAl- lowed=y(Accessed 20 July, 2020) https://ncdc.gov.ng/themes/common/docs/protocols/56_1510840387.pdf https://ncdc.gov.ng/themes/common/docs/protocols/56_1510840387.pdf https://ncdc.gov.ng/themes/common/docs/protocols/56_1510840387.pdf http://www.ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2190 http://www.ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2190 http://www.ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2190 http://www.ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2190 http://www.ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2190 http://www.afro.who.int/publications/multi-sectoral-national-action-plan-antimicrobial-resistance-2017-2027(Accessed http://www.afro.who.int/publications/multi-sectoral-national-action-plan-antimicrobial-resistance-2017-2027(Accessed http://www.afro.who.int/publications/multi-sectoral-national-action-plan-antimicrobial-resistance-2017-2027(Accessed http://www.afro.who.int/publications/multi-sectoral-national-action-plan-antimicrobial-resistance-2017-2027(Accessed http://documents1.worldbank.org/curated/en/735071472096342073/pdf/108008-v1-REVISED-PUBLIC-Main-report-TICAD-UHC-Framework-FINAL.pdf http://documents1.worldbank.org/curated/en/735071472096342073/pdf/108008-v1-REVISED-PUBLIC-Main-report-TICAD-UHC-Framework-FINAL.pdf http://documents1.worldbank.org/curated/en/735071472096342073/pdf/108008-v1-REVISED-PUBLIC-Main-report-TICAD-UHC-Framework-FINAL.pdf http://documents1.worldbank.org/curated/en/735071472096342073/pdf/108008-v1-REVISED-PUBLIC-Main-report-TICAD-UHC-Framework-FINAL.pdf http://documents1.worldbank.org/curated/en/735071472096342073/pdf/108008-v1-REVISED-PUBLIC-Main-report-TICAD-UHC-Framework-FINAL.pdf https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_summary_EN.pdf?ua=1 https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_summary_EN.pdf?ua=1 https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_summary_EN.pdf?ua=1 https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_summary_EN.pdf?ua=1 http://www.who.int/healthsystems/strategy/everybodys_business.pdf http://www.who.int/healthsystems/strategy/everybodys_business.pdf http://www.who.int/healthsystems/strategy/everybodys_business.pdf http://www.afro.who.int/publications/first-who-africa-health-forum-report http://www.afro.who.int/publications/first-who-africa-health-forum-report http://www.afro.who.int/publications/first-who-africa-health-forum-report http://www.socialprotection.org/discover/blog/health-care-nigeria-challenges-and-recommendations(1 http://www.socialprotection.org/discover/blog/health-care-nigeria-challenges-and-recommendations(1 http://www.socialprotection.org/discover/blog/health-care-nigeria-challenges-and-recommendations(1 http://www.socialprotection.org/discover/blog/health-care-nigeria-challenges-and-recommendations(1 http://www.apps.who.int/iris/bitstream/handle/10665/204355/9789241506342_eng.pdf?sequence=1&isAllowed=y(Accessed http://www.apps.who.int/iris/bitstream/handle/10665/204355/9789241506342_eng.pdf?sequence=1&isAllowed=y(Accessed http://www.apps.who.int/iris/bitstream/handle/10665/204355/9789241506342_eng.pdf?sequence=1&isAllowed=y(Accessed http://www.apps.who.int/iris/bitstream/handle/10665/204355/9789241506342_eng.pdf?sequence=1&isAllowed=y(Accessed http://www.apps.who.int/iris/bitstream/handle/10665/204355/9789241506342_eng.pdf?sequence=1&isAllowed=y(Accessed Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 15 | P a g e © 2021 Joshua et al; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 48. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, Hardcastle TC, Roques C, Salameh P. Drivers of Antibiotic Resistance Transmission in Low and Middle-In- come Countries from a “One Health” Perspective—A Review. Antibiotics 2020, 9, 372; doi:10.3390/antibiot- ics9070372. www.mdpi.com/jour- nal/antibiotics (Accessed 1 Novem- ber, 2020). 49. Centers for Disease Control and Pre- vention. Core Elements of Hospital Antibiotic Stewardship Programs; US Department of Health and Hu- man Services, CDC: Atlanta, GA, USA, 2014. 50. World Bank Group. Operational Framework for Strengthening Hu- man, Animal, and Environmental Public Health Systems at Their Inter- face; International Bank for Recon- struction and Development/The World Bank: Washington, DC, USA, 2018. MendelsonM.; Matsoso M.P. The World Health Organization: The global action plan for antimicrobial resistance. South Afr. Med. J 2015, 105, 325. __________________________________________________________________________ http://www.mdpi.com/journal/antibiotics http://www.mdpi.com/journal/antibiotics